Skip to main content
Sansure Biotech Inc. logo

Sansure Biotech Inc. — Investor Relations & Filings

Ticker · 688289 ISIN · CNE1000043J1 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 870 across all filing types
Latest filing 2025-08-05 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 688289

About Sansure Biotech Inc.

https://www.sansureglobal.com/

Sansure Biotech Inc. specializes in the development and manufacture of molecular diagnostic products and genetic testing solutions. The company utilizes proprietary technologies, such as the "One-tube" fast extraction method and advanced magnetic bead technology, to provide high-sensitivity PCR diagnostic kits. Its product portfolio covers a wide range of clinical applications, including infectious disease screening for hepatitis, respiratory infections, and sexually transmitted infections, as well as oncology and maternal health. Sansure also provides integrated laboratory automation systems, including nucleic acid extractors and real-time PCR instruments, designed to streamline clinical workflows and improve diagnostic efficiency for healthcare providers and research institutions globally.

Recent filings

Filing Released Lang Actions
上海妙道企业管理咨询有限公司关于圣湘生物科技股份有限公司2025年限制性股票激励计划授予相关事项之独立财务顾问报告
Capital/Financing Update Classification · 95% confidence The document is titled as an "Independent Financial Advisor Report" by Shanghai Miaodao Enterprise Management Consulting Co., Ltd. regarding the 2025 Restricted Stock Incentive Plan of Shengxiang Bio-Technology Co., Ltd. It contains detailed information about the stock incentive plan, including approval procedures, grant details, conditions, and the advisor's verification opinions. The document is 7,614 characters long, which is substantial and contains detailed substantive content rather than just an announcement or a brief summary. It is not a general annual or quarterly report, nor is it a regulatory filing or a proxy solicitation. It is a specialized advisory report related to a capital incentive plan, which aligns with a Capital/Financing Update (CAP) category, as it deals with stock grants and equity incentives, which are financing-related activities. Therefore, the appropriate classification is CAP with high confidence.
2025-08-05 Chinese
湖南启元律师事务所关于圣湘生物科技股份有限公司2025年限制性股票激励计划授予相关事项的法律意见书
Regulatory Filings
2025-08-05 Chinese
圣湘生物科技股份有限公司关于使用部分暂时闲置募集资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement by 圣湘生物科技股份有限公司 regarding the use of temporarily idle raised funds for cash management. It details the board meeting resolution, the amount of funds involved, investment product types, risk control measures, and compliance with regulatory requirements. The document is not a full financial report, audit, or earnings release but rather a disclosure about the company's financing activities related to the management of raised funds. It does not contain financial statements or detailed financial analysis but focuses on the use of capital raised from a previous public offering. The document length is about 3,000 characters, which is relatively short and typical for an announcement. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2025-08-05 Chinese
圣湘生物科技股份有限公司董事会薪酬与考核委员会关于2025年限制性股票激励计划激励对象名单的核查意见（截至授予日）
Remuneration Information Classification · 95% confidence The document is a formal opinion from the Board's Remuneration and Assessment Committee regarding the verification of the list of incentive recipients under a 2025 restricted stock incentive plan. It discusses compliance with relevant laws and regulations, eligibility of incentive recipients, and approval of the grant date and price. This content pertains to executive compensation and stock incentive plans, which falls under remuneration information. The document is not an annual report, audit report, or general regulatory filing, but specifically relates to compensation and incentive plans for executives and key employees. Therefore, the appropriate classification is Remuneration Information (DEF 14A). The document length is short and focused on remuneration details, not a broader report or announcement.
2025-08-05 Chinese
圣湘生物科技股份有限公司关于完成董事会换届选举暨聘任高级管理人员及证券事务代表的公告
Board/Management Information Classification · 100% confidence The document is an official announcement from 圣湘生物科技股份有限公司 regarding the completion of the board of directors' re-election and the appointment of senior management and securities affairs representatives. It details the election results of the board members, the appointment of the chairman and committee members, the hiring of senior executives, and changes in the supervisory board structure. The content focuses on governance changes and management appointments rather than financial results, audit information, or shareholder voting results. It is not a full annual or interim report, nor is it a call transcript or earnings release. The document is a formal announcement about board and management changes, fitting the category of Board/Management Information (MANG). The document length (5214 characters) and detailed content confirm it is not a brief notice or a report publication announcement.
2025-08-05 Chinese
圣湘生物科技股份有限公司第三届董事会2025年第一次临时会议决议公告
Board/Management Information Classification · 100% confidence The document is an announcement of resolutions passed at the company's third board meeting in 2025, including election and appointment of board members and senior management, as well as approvals related to cash management and stock incentive plans. It details the board meeting date, attendance, voting results, and specific appointments. The content focuses on changes in the board and senior management positions, which aligns with the category for announcements of changes in the company's board of directors or senior management. The document is not a full report, financial statement, or earnings release, but a formal announcement of management and board changes.
2025-08-05 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.